搜索筛选:
搜索耗时0.3019秒,为你在为你在102,265,124篇论文里面共找到 2 篇相符的论文内容
发布年度:
LUX-Lung 6: A randomized, open-label, Phase Ⅲ study of afatinib vs.gemcitabine/cisplatin as first-li
[会议论文] 作者：Yi-Long Wu,Sarayut L Geater,Cheng-Ping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Jian Hua Shi,Mei Hou,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
...
LUX-Lung 6: A randomized, open-label, Phase Ⅲ study of afatinib vs.gemcitabine/cisplatin as first-li
[会议论文] 作者：Yi-Long Wu,Sarayut L Geater,Cheng-Ping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Jian Hua Shi,Mei Hou,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
Background: Afatinib is an oral, irreversible, ErbB Family Blocker, blocking signaling from EGFR (ErbB1), HER2 (ErbB2) and ErbB4.Afatinib was superior to first-line pemetrexed/cisplatin in terms of pr...
相关搜索：
